Goserelin Research: What 2,187 Studies Show (2026) | RetatrutideCompare

Goserelin — 2,187 studies indexed on PubMed. GnRH super-agonist delivered as a biodegradable subcutaneous depot. Half-life: ~4 hours (subcutaneous depot). FDA status: FDA-approved (1989).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Goserelin?

There are approximately 2,187 studies indexed on PubMed that mention Goserelin (Zoladex), based on a search last updated 2026-06-18.

Is Goserelin FDA-approved?

FDA status: FDA-approved (1989).

How does Goserelin work?

GnRH super-agonist delivered as a biodegradable subcutaneous depot.

Reference facts

Also known as: Zoladex
Category: GnRH & Reproductive
Mechanism of action: GnRH super-agonist delivered as a biodegradable subcutaneous depot.
Targets: GnRH receptor
Indications under research or approved: Prostate cancer, Breast cancer (premenopausal, ER+), Endometriosis
Regulatory status (reference entry): FDA-approved (1989)
Half-life: ~4 hours (subcutaneous depot)
Sequence notes: Decapeptide pyroGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-AzaGly-NH2.
Molecular weight (Da): 1269
Originator / sponsor: AstraZeneca
First reported: 1976

Primary References

Zoladex FDA label

Explore research articles about Goserelin

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.